David Dornan
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 2%
- Cancer-related Molecular Pathways
Papers in
- Oncology 23
- Cancer-related Molecular Pathways 10
- CAR-T cell therapy research 5
-
- Ubiquitin and proteasome pathways 7
- Co-authors
- Vishva M. Dixit (5 shared papers)Harumi Shimizu (6 shared papers)Ingrid E. Wertz (2 shared papers)David Arnott (2 shared papers)Ted R. Hupp (5 shared papers)Karen O’Rourke (3 shared papers)Hartmut Koeppen (4 shared papers)Patrick J. Dowd (2 shared papers)
- Journals
- Blood (6 papers)Cancer Research (4 papers)Nature (2 papers)Science (2 papers)Journal of Biological Chemistry (2 papers)
- Partner nations
- United StatesUnited KingdomDenmark
In The Last Decade
David Dornan
36 papers receiving 3.1k citations
David Dornan's Hit Papers
Peers
Comparison fields: 5 of 91
- Cancer Research 816
- Oncology 1.4k
- Molecular Biology 2.5k
- Biotechnology 167
- Cell Biology 281
Countries citing papers authored by David Dornan
This map shows the geographic impact of David Dornan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Dornan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Dornan more than expected).
Fields of papers citing papers by David Dornan
This network shows the impact of papers produced by David Dornan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Dornan. The network helps show where David Dornan may publish in the future.
Co-authors
The 25 scholars most cited alongside David Dornan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The ubiquitin ligase COP1 is a critical negative regulator of p53 Hit paper breakdown → | 2004 | 568 |
| 2 | Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival Hit paper breakdown → | 2009 | 510 |
| 3 | 2004 | 301 | |
| 4 | 2011 | 252 | |
| 5 | 2009 | 197 | |
| 6 | 2011 | 118 | |
| 7 | 2013 | 115 | |
| 8 | 2006 | 112 | |
| 9 | 2004 | 110 | |
| 10 | 2002 | 99 | |
| 11 | 2003 | 92 | |
| 12 | 2003 | 87 | |
| 13 | 2002 | 79 | |
| 14 | 2001 | 73 | |
| 15 | 2013 | 69 | |
| 16 | 2004 | 65 | |
| 17 | 2014 | 59 | |
| 18 | 2015 | 57 | |
| 19 | 2012 | 51 | |
| 20 | 2013 | 49 |
About David Dornan
David Dornan is a scholar working on Oncology, Molecular Biology, Immunology, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 38 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Ubiquitin and proteasome pathways (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Immunotherapy and Immune Responses (6 papers), MicroRNA in disease regulation (5 papers), CAR-T cell therapy research (5 papers) and Cancer Research and Treatments (4 papers). The work is most often cited by research in Cancer Research (816 citations), Oncology (1.4k citations), Molecular Biology (2.5k citations), Biotechnology (167 citations) and Cell Biology (281 citations). David Dornan has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include Vishva M. Dixit, Harumi Shimizu, Ingrid E. Wertz, David Arnott, Ted R. Hupp, Karen O’Rourke, Hartmut Koeppen, Patrick J. Dowd, Gretchen Frantz and Yue Peng. Their work appears in journals such as Blood, Cancer Research, Nature, Science and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.